Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

Company Performance - Cerus reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.03, and an improvement from a loss of $0.03 per share a year ago, representing an earnings surprise of 33.33% [1] - The company posted revenues of $46.02 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 4.35% and up from $39.77 million in the same quarter last year [2] - Over the last four quarters, Cerus has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Cerus shares have declined approximately 21.3% since the beginning of the year, contrasting with the S&P 500's gain of 22.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $49.2 million, and for the current fiscal year, it is -$0.13 on revenues of $176.7 million [7] Industry Context - The Medical - Products industry, to which Cerus belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Cerus's stock performance [5]